OncoC4, Inc. is a biotechnology company focused on developing innovative immunotherapies for hard-to-treat cancers and Alzheimer's disease. The company utilizes advanced scientific pathways involving immune checkpoints like CTLA-4, CD24, and Siglec to enhance the immune system's ability to identify and eliminate cancer cells. Their goal is to create safer and more effective therapies. The product pipeline includes a variety of therapeutic modalities such as monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and CAR T-cell therapies. These treatments are designed to tackle the complexities of cancer and neurodegenerative diseases by targeting both innate and adaptive immune checkpoints. Founded by leading immunologists, OncoC4 is supported by a team with extensive experience in clinical development and business strategy. The company is headquartered in Rockville, Maryland, and is dedicated to advancing its clinical pipeline through research partnerships and investor collaborations.
我們正在追蹤 OncoC4, Inc. 的市場擴張
OncoC4, Inc. 的國際擴張與競爭對手的比較
OncoC4, Inc.你長條顯示所比較各公司之間的相對規模。
欄位5| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
 OncoC4, Inc.你 | 0 | 0 | — | 0 | 0 |
目前並無招聘
註冊以追蹤此公司，並在發生變化時第一時間獲得提醒。
無進行中的廣告活動
註冊以追蹤此公司，並在發生變化時第一時間獲得提醒。
BioNTech和OncoC4的Gotistobart在肺癌患者中顯示比化療降低超過50%的死亡風險，有潛力成為無化療的單一療法。
OncoC4在中國宣武醫院為首位參與者進行ONC-841阿茲海默症1/2期試驗給藥,已獲NMPA批准。ONC-841是全球首個抗SIGLEC 10抗體。
OncoC4宣布gotistobart獲中國NMPA突破性療法認定，用於治療鱗狀非小細胞肺癌，加速其在中國的開發和審查。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 OncoC4, Inc. 業務、市場及增長訊號的快速解答。
